

Anissa Abi-Dargham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4808283/publications.pdf>

Version: 2024-02-01

81
papers

8,344
citations

101543

36
h-index

79698

73
g-index

86
all docs

86
docs citations

86
times ranked

7783
citing authors

#	ARTICLE	IF	CITATIONS
1	The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment. Archives of General Psychiatry, 2012, 69, 776-86.	12.3	769
2	Prefrontal Dopamine D ₁ Receptors and Working Memory in Schizophrenia. Journal of Neuroscience, 2002, 22, 3708-3719.	3.6	688
3	Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry, 1999, 46, 56-72.	1.3	664
4	Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 285-300.	4.3	510
5	Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia. Archives of General Psychiatry, 2010, 67, 231.	12.3	468
6	Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends in Neurosciences, 2019, 42, 205-220.	8.6	441
7	Alterations of Benzodiazepine Receptors in Type II Alcoholic Subjects Measured With SPECT and [¹²³ I]Iomazenil. American Journal of Psychiatry, 1998, 155, 1550-1555.	7.2	395
8	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. JAMA Psychiatry, 2015, 72, 316.	11.0	304
9	Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology, 2004, 7, S1-S5.	2.1	295
10	Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia. Neuroscientist, 2003, 9, 404-416.	3.5	243
11	Pathway-Specific Dopamine Abnormalities in Schizophrenia. Biological Psychiatry, 2017, 81, 31-42.	1.3	221
12	Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects. Biological Psychiatry, 2009, 65, 1091-1093.	1.3	187
13	The search for imaging biomarkers in psychiatric disorders. Nature Medicine, 2016, 22, 1248-1255.	30.7	180
14	GABA level, gamma oscillation, and working memory performance in schizophrenia. NeuroImage: Clinical, 2014, 4, 531-539.	2.7	151
15	Deficits in Predictive Coding Underlie Hallucinations in Schizophrenia. Journal of Neuroscience, 2014, 34, 8072-8082.	3.6	151
16	Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry, 2005, 20, 15-27.	0.2	144
17	Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophrenia Research, 2014, 152, 325-332.	2.0	144
18	Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5108-5117.	7.1	136

#	ARTICLE	IF	CITATIONS
19	Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. <i>Biological Psychiatry</i> , 2004, 55, 1001-1006.	1.3	126
20	A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine. <i>Current Biology</i> , 2018, 28, 503-514.e4.	3.9	120
21	Increased prefrontal cortical D ₁ receptors in drug naïve patients with schizophrenia: a PET study with [¹¹ C]NNC112. <i>Journal of Psychopharmacology</i> , 2012, 26, 794-805.	4.0	112
22	Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e31-e31.	2.2	109
23	PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. , 1999, 32, 93-109.		103
24	Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. <i>Psychopharmacology</i> , 2016, 233, 3503-3512.	3.1	101
25	Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. <i>British Journal of Psychiatry</i> , 2014, 204, 420-429.	2.8	98
26	Mechanisms of Working Memory Impairment in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 80, 617-626.	1.3	96
27	Effects of the D1 Dopamine Receptor Agonist Dihydropyridine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 446-453.	5.4	83
28	Alterations of Serotonin Transmission in Schizophrenia. <i>International Review of Neurobiology</i> , 2007, 78, 133-164.	2.0	82
29	Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. , 1999, 31, 302-308.		73
30	Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. <i>Biological Psychiatry</i> , 2020, 87, 215-224.	1.3	69
31	Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naïve healthy volunteers: results from a large cohort. <i>European Neuropsychopharmacology</i> , 2003, 13, 459-468.	0.7	60
32	Dopamine D ₁ signaling organizes network dynamics underlying working memory. <i>Science Advances</i> , 2016, 2, e1501672.	10.3	59
33	Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males. <i>Neuropsychopharmacology</i> , 2016, 41, 2596-2605.	5.4	59
34	Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 862.	11.0	58
35	An integrative framework for perceptual disturbances in psychosis. <i>Nature Reviews Neuroscience</i> , 2019, 20, 763-778.	10.2	53
36	Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. <i>NeuroImage</i> , 2020, 208, 116457.	4.2	51

#	ARTICLE	IF	CITATIONS
37	A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 428-435.	4.0	49
38	The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. <i>Biological Psychiatry</i> , 2019, 86, 502-511.	1.3	42
39	The 5-HT 2A receptor and serotonin transporter in Asperger's Disorder: A PET study with [11 C]MDL 100907 and [11 C]DASB. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 230-234.	1.8	41
40	In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2011, 36, 887-895.	5.4	41
41	Motivational Context Modulates Prediction Error Response in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 1467-1475.	4.3	37
42	Dynamic Connectivity between Brain Networks Supports Working Memory: Relationships to Dopamine Release and Schizophrenia. <i>Journal of Neuroscience</i> , 2016, 36, 4377-4388.	3.6	34
43	Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2018, 84, 563-573.	1.3	31
44	A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. <i>Neuropsychopharmacology</i> , 2020, 45, 786-792.	5.4	29
45	Evidence for Dopamine Abnormalities in the Substantia Nigra in Cocaine Addiction Revealed by Neuromelanin-Sensitive MRI. <i>American Journal of Psychiatry</i> , 2020, 177, 1038-1047.	7.2	26
46	Serotonin transporter availability in impulsive aggressive personality disordered patients: A PET study with [11C]DASB. <i>Journal of Psychiatric Research</i> , 2014, 58, 147-154.	3.1	25
47	Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population. <i>JAMA Psychiatry</i> , 2017, 74, 104.	11.0	24
48	Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder. <i>Behavioural Brain Research</i> , 2021, 398, 113004.	2.2	23
49	Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2015, 168, 373-376.	2.0	22
50	Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates. <i>Nuclear Medicine and Biology</i> , 2014, 41, 343-349.	0.6	21
51	Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems.. <i>Psychology of Addictive Behaviors</i> , 2015, 29, 864-874.	2.1	21
52	Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. <i>Psychiatry Research</i> , 2019, 275, 78-85.	3.3	21
53	From "bedside" to "bench" and back: A translational approach to studying dopamine dysfunction in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 110, 174-179.	6.1	19
54	Aberrant Temporal Connectivity in Persons at Clinical High Risk for Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 696-705.	1.5	18

#	ARTICLE	IF	CITATIONS
55	Molecular imaging in alcohol dependence. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 125, 293-311.	1.8	17
56	Two Hypotheses on the High Incidence of Dementia in Psychotic Disorders. JAMA Psychiatry, 2021, 78, 1305.	11.0	17
57	Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 591-598.	1.5	16
58	Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders. Seminars in Nuclear Medicine, 2017, 47, 54-63.	4.6	15
59	Is it Pre- or Postsynaptic? Imaging Striatal Dopamine Excess in Schizophrenia. Biological Psychiatry, 2018, 83, 635-637.	1.3	15
60	Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO. Psychopharmacology, 2020, 237, 519-527.	3.1	15
61	Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis. Neuropsychopharmacology, 2016, 41, 1241-1250.	5.4	14
62	Schizophrenia: The Role of Dopamine and Glutamate. Journal of Clinical Psychiatry, 2014, 75, 274-275.	2.2	14
63	Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression. European Neuropsychopharmacology, 2021, 53, 89-100.	0.7	12
64	The Neurobiology of Schizophrenia. , 0, , 301-316.		11
65	<scp>Crossâ€Scanner</scp> Harmonization of <scp>Neuromelaninâ€Sensitive MRI</scp> for Multisite Studies. Journal of Magnetic Resonance Imaging, 2021, 54, 1189-1199.	3.4	10
66	Emerging Treatments in Schizophrenia. Journal of Clinical Psychiatry, 2022, 83, .	2.2	10
67	Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Molecular Psychiatry, 2021, 26, 2504-2513.	7.9	9
68	The Striatum and Dopamine. JAMA Psychiatry, 2014, 71, 489.	11.0	8
69	A Dual Hit Model for Dopamine in Schizophrenia. Biological Psychiatry, 2017, 81, 2-4.	1.3	8
70	Deep rTMS of the insula and prefrontal cortex in smokers with schizophrenia: Proof-of-concept study. NPJ Schizophrenia, 2022, 8, 6.	3.6	7
71	Amphetamine-induced striatal dopamine release in schizotypal personality disorder. Psychopharmacology, 2020, 237, 2649-2659.	3.1	4
72	Is It in Our Genes: Oxytocin, Dopamine, Stress, and Sex. Biological Psychiatry, 2012, 72, 171-172.	1.3	3

#	ARTICLE	IF	CITATIONS
73	Imaging the "GABA Shift" in Schizophrenia. American Journal of Psychiatry, 2015, 172, 1062-1063.	7.2	1
74	Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Adopt Neuroscience-Based Nomenclature. Biological Psychiatry, 2016, 80, 2-3.	1.3	1
75	Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Adopt Neuroscience-Based Nomenclature. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 300-301.	1.5	1
76	NPP: Our Designs for the Future. Neuropsychopharmacology, 2017, 42, 1371-1372.	5.4	0
77	27. THE ROLE OF DOPAMINE IN SHAPING CIRCUITRY RELATED TO SCHIZOPHRENIA AND ADDICTION. Schizophrenia Bulletin, 2018, 44, S44-S44.	4.3	0
78	3.3 DISTURBANCES IN NEURAL OSCILLATIONS, GLUTAMATE, AND GABA: EFFECTS OF KETAMINE AND COMPARISON TO SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S2-S2.	4.3	0
79	43.4 THE ROLE OF MOLECULAR IMAGING IN GUIDING DRUG DEVELOPMENT. Schizophrenia Bulletin, 2018, 44, S71-S71.	4.3	0
80	Letter to the Editor: A Novel Therapeutic for Opioid Use Disorder Targeting the Cholinergic System. American Journal on Addictions, 2019, 28, 235-237.	1.4	0
81	Ubiquitous Dopamine Deficit Hypotheses in Cocaine Use Disorder Lack Support: Response to Leyton. American Journal of Psychiatry, 2021, 178, 469-470.	7.2	0